THE NOVEL GEMCITABINE PHOSPHOLIPID CONJUGATE KPC34 HAS ACTIVITY AGAINST MULTIPLE MODELS OF RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA

Acute leukemias are cancers of the blood and bone marrow that affect thousands of Americans annually. These diseases can be myeloid or lymphoid in origin. Common components of therapy for both types of disease involve cytarabine and an anthracycline. After initially responding to treatment, most patients eventually relapse with disease that is resistant to conventional modalities. There is a pressing need for novel therapeutic agents to treat the acute leukemias, especially in the relapsed setting.

Grantor dc:publisher

Wake Forest University

Year dc:date.issued

2015

Author dc:creator

• Alexander, Peter M.

• Chemoresistance

Language dc:language.iso

en

Handle dc:identifier.uri

http://hdl.handle.net/10339/57145

OAI identifier oai:identifier

oai:wakespace.lib.wfu.edu:10339/57145